Form 4 for AMGN Amgen

Accepted 2021-11-03 00:00:00 ET · period of report 2021-11-01 · accession 0001127602-21-028364 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2021-11-03	2021-11-01	AMGN	Griffith Peter H.	EVP, CFO	F - Tax	$206.97	-2,661	23.7K	-10%	-$550.7K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-11-01	F	D	2,661	$206.97	23,700	D	—	—	(F1) These shares include the following RSUs granted under the Company's equity plans: 12,296 RSUs which vest in one installment of 6,056 on 11/1/2022 and one installment of 6,240 on 11/1/2023; 3,384 RSUs which vest in installments of 1,116 on 5/5/2022, 1,117 on 5/5/2023 and 1,151 on 5/5/2024; and 3,338 RSUs which vest in installments of 1,101 on 4/30/2023, 1,102 on 4/30/2024 and 1,135 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. (F2) These shares include 930 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.